Intensive lifestyle intervention seems to be of little benefit in terms of lowering heart failure (HF) risk in type 2 diabetes patients with overweight or obesity when compared with standard diabetes support and education, although weight loss and sustained improvements in cardiorespiratory fitness (CRF) may be protective, according to a study.
The glucagon-like peptide-1 receptor agonist liraglutide has been shown to be safe in patients with type 2 diabetes (T2D) with or without a history of New York Heart Association (NYHA) functional class I to III heart failure (HF), according to a study.
A recent retrospective study from Singapore identified several factors associated with a higher risk of mortality following hip fracture, including male sex, older age, and a higher number of comorbidities.
The risk of cardiovascular (CV) disease (CVD) is significantly higher among patients with rheumatoid arthritis (RA) than those with type 2 diabetes (T2D), results of the CARRÉ* study reveal. Such risk persisted even after adjusting for traditional CV risk factors, which suggests that systemic inflammation is an independent contributor to CV risk.
In the primary care setting, adding liraglutide to intensive behavioural therapy (IBT) conferred greater weight loss than IBT alone among individuals with obesity, results from the phase IIIB SCALE* IBT study showed.
Knee osteoarthritis (OA), whether symptomatic or radiographic, contributes to an increased risk of all-cause mortality, with the risk increase from symptomatic knee OA partially attributed to its effect on disability and quality of life (QoL).
It takes just less than 4 days for COVID-19 to spread from one person to another and cause symptoms, and more than 10 percent of the cases are infected by a person who has caught the virus but yet to show symptoms, recent studies suggest.